Comparing the current results to its competitors, Vericel reported Revenue increase in the 1 quarter 2026 by 30.09 % year on year. The sales growth was above Vericel's competitors' average revenue growth of 17.71 %, achieved in the same quarter.
Vericel Corporation, despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 62.83 %
Vericel's Comment on Competition and Industry Peers
The biotechnology and medical device industries are characterized by intense competition and rapidly advancing technology. Competitors include multinational medical device companies, pharmaceutical firms, biotechnology companies involved in processing and distributing human tissue and tissue-derived products, and stem cell companies specializing in tissue engineering, regenerative medicine, orthopedics, and neural medicine. Many competitors possess extensive technical, research and development, financial, and sales and marketing resources. Smaller companies often enter strategic collaborations or joint ventures with larger firms to enhance research, development, and commercialization efforts. Additionally, academic institutions, governmental agencies, and other research organizations conduct research that may lead to directly competitive products. Competitors may secure patent protection, obtain regulatory approvals, and commence commercial sales prior to the company. For the treatment of cartilage defects, available options include arthroscopic debridement/chondroplasty, marrow stimulation techniques such as microfracture, osteochondral autografts or allograft-derived tissue products for smaller injuries, osteochondral allografts, and autologous chondrocyte implants like MACI for larger injuries. These treatment methods constitute the primary competition for MACI in the U.S. market.
Xtant Medical Holdings Inc operates as a medical technology company that focuses on the development, production, and distribution of regenerative medical products and devices. It primarily offers orthopedic and spinal surgical implants and instruments, providing solutions to surgeons and patients for enhancing healing and improving patient outcomes.
Lineage Cell Therapeutics Inc is a biotechnology company primarily focused on developing and commercializing novel cell therapies for degenerative diseases. They leverage their proprietary cell-based technology to create therapeutic products that target specific conditions like spinal cord injuries, age-related macular degeneration, and osteoarthritis. The company aims to provide innovative and effective treatments by utilizing their expertise in cellular biology and therapeutic research.
Mediwound Ltd operates through the development, manufacturing, and commercialization of biopharmaceutical products. Their business model primarily involves leveraging their expertise in biotechnology to create innovative therapies for the treatment of severe burns, chronic wounds, and other healing disorders.
Ocugen Inc's business model is focused on the development and commercialization of innovative gene therapies to treat rare and underserved ocular diseases, with a particular emphasis on underserved patient populations. They aim to leverage their expertise in gene therapy and partnerships to advance novel treatments and bring them to market, ultimately improving the lives of patients in need.
Orthofix Medical Inc is a company that focuses on developing and selling medical devices and orthopedic solutions to healthcare providers and patients.
Sources:
Vericel Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Vericel Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
